Speaker Profile

Ph.D., Founder & Chief Strategy Officer, Atreca, Inc.

Biography
Dr. Serafini is one of the three principal founders of Atreca and was CEO from the company’s inception in 2010 until 2018. In his role as Chief Strategy Officer, Dr. Serafini is responsible directly for research, preclinical development, technology, and intellectual property. Before co-founding Atreca, he was Chief Scientific Officer of Nuon Therapeutics, a development-stage biotechnology company. Previously, Dr. Serafini was a founder of Renovis, a public biotechnology company, where he served as an executive officer in multiple technical and business management roles, including leading the research and M&A functions. Prior to founding Renovis, Dr. Serafini was an award-winning faculty member in the Department of Molecular and Cell Biology at the University of California, Berkeley, where he established the university’s Functional Genomics Laboratory.


Talk


Emerging Therapeutics Showcase:
Atreca, Inc.

Atreca is a clinical-stage biotechnology company inverting the traditional approach to cancer drug discovery. Atreca’s unique platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors.

The Next Frontier of Therapeutic Antibodies
Addressing unmet medical need in oncology and identifying novel targets at a more rapid pace.

 Session Abstract – PMWC 2023 Silicon Valley

Showcase Track S1 - January 27 9.45 A.M.-1.45 P.M.


The PMWC 2023 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.

  • Emerging Therapeutics/Cell Therapy
  • Emerging Therapeutics/CVD
  • Emerging Therapeutics/Gene Therapy
  • Emerging Therapeutics/Immunotherapy
  • Emerging Therapeutics/Radiation Therapy

×

Add Names/PO on Receipt

Apply to Speak at PMWC Silicon Valley by FEB. 29TH

The PMWC team will reply back to a suitable company/topic with an official request for talk/speaker details.

Contact Us:

Fields marked with an * are required 

Contact Us:

Fields marked with an * are required 

Discover What's Next in Precision Medicine!

Join our community today for the latest news, exclusive interviews, and unique insights from world-renowned speakers and experts


Contact Us:

Fields marked with an * are required 

Discount also depends on group size. The bigger group – the bigger discount.

Trouble Registering

Fields marked with an * are required

Stay Tuned For More Information.

Sign up for occasional updates on upcoming conferences, news, and other information. 

Get Updates:

Submit to Speak in the PMWC Showcase

Fields marked with an * are required